# SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery

> **NCT06300411** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **SURGE Therapeutics** · enrollment: 24 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SRG-514

## Key facts

- **NCT ID:** NCT06300411
- **Lead sponsor:** SURGE Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-29
- **Primary completion:** 2026-04-10
- **Final completion:** 2026-04-10
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06300411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06300411, "SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06300411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*